Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey

Autor: Ponzetti, Clemente, Canciani, Monica, Farina, Massimo, Era, Sara, Walzer, Stefan

Publikováno v: ClinicoEconomics and Outcomes Research: CEOR

Introduction Subcutaneous versions of different oncology therapies have been available for patients for a few years, yet patient-relevant and hospital benefits have not been assessed in real life. Methods In order to analyze the impact of subcutaneou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e02e9a31950180899389a572b68a2766
http://europepmc.org/articles/PMC4883807

Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approach.

Autor: Ponzetti C; Gruppo Policlinico di Monza, Alessandria, ANMDO National Association of Hospital Physicians, Bologna., Canciani M; Studio EmmEffe Srl, Milan., Farina M; Studio EmmEffe Srl, Milan., Era S; Roche Spa, Monza, Italy., Walzer S; MArS Market Access & Pricing Strategy GmbH, Weil am Rhein; State University Baden-Wuerttemberg, Health Care Management, Loerrach, Germany.

Publikováno v: ClinicoEconomics and outcomes research : CEOR [Clinicoecon Outcomes Res] 2016 Aug 03; Vol. 8, pp. 353-9. Date of Electronic Publication: 2016 Aug 03 (Print Publication: 2016).